Citeline Podcasts podcast

Special Episode: Topspin and Why Product Demand, Not Coverage, Drives Formulary Power

0:00
49:16
Rewind 15 seconds
Fast Forward 15 seconds
Conventional wisdom says you secure coverage first, then build demand. What if the causality runs the other way? In this special In Vivo podcast episode, senior reporter David Wild talks with Harris Kaplan (managing partner, Litmys), Sal Grouso (senior market access executive), and Roxanne Schwans (founder and CEO, OmniHealth Rx Advisors). Kaplan and Grouso recently published an article in In Vivo titled “Topspin: Why Product Demand Is What Really Matters to PBMs.” The guests argue that a preferred formulary position is rented real estate: it gives a product permission to compete, but it only stays on the shelf if prescription volume justifies it. They explain why a large rebate on a product nobody uses is worth very little, how PBMs think about net cost per member per month (PMPM), and why a product holding under 5% of category share is in a precarious spot. Drawing on real-world cases, including Vyvanse and an oral psoriasis launch, they show how demand and friction (prior authorizations, appeals, patient pull) can change the negotiating dynamic. They also walk through Litmys’s RAMP (Realistic Assessment of Market Potential) model and explain why market access should be at the table as early as Phase II.

More episodes from "Citeline Podcasts"